

| | |
|----------------------------|---|
| 7:30 am – 8:00 am | Registration & Continental Breakfast |
| 8:00 am – 9:30 am | Presentation and Diagnosis <ul style="list-style-type: none"> • Overview of Carcinoid Tumors and Other NETs <ul style="list-style-type: none"> ○ Epidemiology ○ Presentation of Symptoms • Diagnosis of NETs <ul style="list-style-type: none"> ○ Endoscopy & Colonoscopy (include use of octreotide) ○ Pathological classification including minimum data set for biopsy ○ Biomarkers: Interpreting Laboratory Results to Clinical Use ○ Radiological Imaging – Selecting the Right Procedure & Contrast Agents ○ Nuclear Imaging - Which Techniques are Most Efficient for Localizing Tumors? ○ Obstacles In Diagnosis For the Clinician ○ Q & A |
| 9:30 am – 10:15 am | Surgical Options: Making the Right Choice <ul style="list-style-type: none"> • Potential for Crisis & Octreotide Protocol • Surgery Intervention of NETs <ul style="list-style-type: none"> ○ Surgery for Pancreatic Endocrine Tumors ○ Surgery for Small Bowel, Appendiceal and Rectal NETs ○ Removal of Primary in Patients with Liver Mets ○ Resection of Liver Mets ○ Q & A |
| 10:15 am – 10:30 am | BREAK |
| 10:30 am – 11:15 am | The Role of Interventional Radiology in the Diagnosis & Management of NETs <ul style="list-style-type: none"> • Diagnosis of NETs <ul style="list-style-type: none"> ○ Image guided biopsy ○ CT/Ultrasound/MRI guided treatment • Management of Hepatic Metastases <ul style="list-style-type: none"> ○ Cytoreduction ○ Embolotherapy & Ablation ○ Q & A |
| 11:15 am – 12:00 pm | Management of Hormonal Syndromes from NETs <ul style="list-style-type: none"> • Carcinoid Syndrome <ul style="list-style-type: none"> ○ Symptomatic Control (octreotide, lanreotide pasireotide) ○ Disease Stabilization and Improved Survival (PROMID study) ○ Carcinoid Heart Disease • Gastrinomas (ZES Syndrome) • Glucagonoma • Insulinoma • VIPoma <ul style="list-style-type: none"> ○ Q & A |
| 12:00 pm – 12:15 pm | Merkel Cell |
| 12:15 pm – 1:15 pm | LUNCH |
| 1:15 pm – 2:15 pm | Medical Management of NETs - <ul style="list-style-type: none"> • Systemic Therapies <ul style="list-style-type: none"> ○ Overview Cytotoxic Therapies ○ Clinical Development of VEGF Pathway Inhibitors in NETs ○ mTOR Inhibitors – Where Are We Now? ○ Peptide Receptor Radionuclide Therapy - When & What Is Coming to US? ○ Q & A |
| 2:15 pm – 3:00 pm | Developing a Multidisciplinary Treatment Plan – Case Presentations with Panel Discussion <ul style="list-style-type: none"> ○ Q & A |